# RIGL catalysts: RIGEL PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rigl/catalysts

> RIGEL PHARMACEUTICALS INC (RIGL) has 2 upcoming catalysts. The next is the olutasidenib + tmz primary completion, June 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | RIGEL PHARMACEUTICALS INC |
| Ticker | RIGL (Nasdaq) |
| SEC CIK | 1034842 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rigl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2022 | [TAVALISSE (fostamatinib) topline data readout](https://sec-api.dev/pdufa/fostamatinib) | RIGL |  | completed, missed | "In June 2022, we announced top-line efficacy and safety data results of the trial, and the results did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm)) |
| Nov 2022 | [TAVALISSE (fostamatinib) topline data readout](https://sec-api.dev/pdufa/fostamatinib) | RIGL |  | completed, missed | "We previously announced in November 2022 the top-line results did not meet statistical significance in the primary efficacy endpoint." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm)) |
| Dec 2022 | [REZLIDHIA (olutasidenib) FDA approval](https://sec-api.dev/pdufa/olutasidenib) | RIGL |  | completed, approved | "In December 2022, the FDA approved REZLIDHIA capsules for the treatment of adult patients with R/R AML with IDH1 mutation as detected by an FDA-approved test, and we began the commercialization of REZLIDHIA and made it available to patients." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1034842/000110465925106268/rigl-20250930x10q.htm)) |
| March 4, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Calif., March 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and full year ended December 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925020313/tm258144d1_ex99-1.htm)) |
| May 6, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/tm2514128d1_ex99-1.htm)) |
| August 5, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/tm2522417d2_ex99-1.htm)) |
| November 4, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/tm2530133d1_ex99-1.htm)) |
| March 3, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "SOUTH SAN FRANCISCO, Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended December 31, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/rigl-20260303xex991q42025r.htm)) |
| May 5, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/rigl-20260505xex991q12026r.htm)) |
| August 4, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804xex991q22026r.htm)) |
| November 5, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "Rigel Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000062/rigl-20261105xex991q32026r.htm)) |
| June 2029 | [Olutasidenib + tmz primary completion](https://sec-api.dev/pdufa/olutasidenib-tmz) | RIGL | High Grade Glioma; Astrocytoma; Astrocytoma, Grade III | scheduled | "NCT06161974 (Study of Olutasidenib and Temozolomide in HGG): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Rigel Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161974)) |
| Jun to Sep 2029 | [Olutasidenib + tmz topline data readout](https://sec-api.dev/pdufa/olutasidenib-tmz) | RIGL | High Grade Glioma; Astrocytoma; Astrocytoma, Grade III | scheduled | "NCT06161974 (Study of Olutasidenib and Temozolomide in HGG): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Rigel Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161974)) |

## Drugs

- [TAVALISSE (fostamatinib)](https://sec-api.dev/pdufa/fostamatinib): 
- [REZLIDHIA (olutasidenib)](https://sec-api.dev/pdufa/olutasidenib): 
- [Olutasidenib + tmz](https://sec-api.dev/pdufa/olutasidenib-tmz): High Grade Glioma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rigl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RIGL catalysts: RIGEL PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rigl/catalysts

```bibtex
@misc{secapidev_companies_rigl_catalysts_20261116,
  title        = {RIGL catalysts: RIGEL PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rigl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rigl_catalysts_20261116","title":"RIGL catalysts: RIGEL PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rigl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
